-
公开(公告)号：US11607426B2
公开(公告)日：2023-03-21
申请号：US16330858
申请日：2017-09-19
Applicant: UNIVERSITY OF SOUTH FLORIDA , THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventor： Shyam S. Mohapatra , Subhra Mohapatra
IPC: A61K35/28 , C12N7/00 , A61P35/00 , A61K45/06 , C12N5/0775
Abstract: The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.
-
公开(公告)号：US20220062382A1
公开(公告)日：2022-03-03
申请号：US17523009
申请日：2021-11-10
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra , Karthick Mayilsamy , Eleni Markoutsa
Abstract: Compositions and methods for treating traumatic brain injury (TBI) are presented. Novel dendriplexes are formed from poly(amidoamine) (PAMAM) dendrimers complexed with shRNA encoding DNA plasmids encapsulating shRNA encoding chemokine ligand 20 (CCL20) gene, chemokine receptor 6 (CCR6) gene, or a combination thereof. The dendriplexes are dually administered, both intranasally and intravenously, prior to administration of stem cells, such as human mesenchymal stem cells (hMSCs) for the treatment of traumatic brain injury (TBI). Administration of the dendriplexes prior to stem cell administration resulted in a decrease in neurodegeneration, neuroinflammation, microgliosis and astrogliosis. In addition, a synergistic increase in brain derived trophic factor (BDNF) was shown by administration of the combination of dendriplex and stem cell administration.
-
公开(公告)号：US10813935B2
公开(公告)日：2020-10-27
申请号：US15904176
申请日：2018-02-23
Applicant: UNIVERSITY OF SOUTH FLORIDA , TRANSGENEX NANOBIOTECH, INC.
Inventor： Subhra Mohapatra , Shyam S. Mohapatra , Mark Howell , Rajesh Nair
IPC: A61K31/517 , A61P35/00 , A61K31/496
Abstract: Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.
-
公开(公告)号：US11951152B1
公开(公告)日：2024-04-09
申请号：US17025277
申请日：2020-09-18
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra , Eleni Markoutsa , Alejandro J. Gonzalez , Heta N. Jadhav
IPC: A61K38/12 , A61K9/127 , A61K9/16 , A61K31/4184 , A61K31/704 , A61K47/08 , A61K47/24 , A61P35/00
CPC classification number: A61K38/12 , A61K9/127 , A61K9/1652 , A61K31/4184 , A61K31/704 , A61K47/08 , A61K47/24 , A61P35/00
Abstract: This disclosure is directed to therapeutic compositions, and more particularly to microparticle compositions for the controlled delivery of telmisartan and actinomycin D.
-
公开(公告)号：US20170219564A1
公开(公告)日：2017-08-03
申请号：US15489823
申请日：2017-04-18
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra
CPC classification number: G01N33/5011 , C12N5/0068 , C12N5/0693 , C12N2533/40 , C12N2533/72 , G01N33/5082 , G01N2500/10
Abstract: Provided herein is a three-dimensional scaffold composition comprising randomly oriented fibers, wherein the fibers comprise a polyethylene glycol-polylactic acid block copolymer (PEG-PLA) and a poly(lactic-co-glycolic acid) (PLGA). Also provided are methods for using the three-dimensional scaffolds described herein.
-
Patent Agency Ranking
公开(公告)号：US09618501B2
公开(公告)日：2017-04-11
申请号：US14447779
申请日：2014-07-31
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra
CPC classification number: G01N33/5011 , C12N5/0068 , C12N5/0693 , C12N2533/40 , C12N2533/72 , G01N33/5082 , G01N2500/10
Abstract: Provided herein is a three-dimensional scaffold composition comprising randomly oriented fibers, wherein the fibers comprise a polyethylene glycol-polylactic acid block copolymer (PEG-PLA) and a poly(lactic-co-glycolic acid) (PLGA). Also provided are methods for using the three-dimensional scaffolds described herein.
-
7.发明申请公开(公告)号：US20140336239A1
公开(公告)日：2014-11-13
申请号：US14361537
申请日：2012-12-03
Applicant: UNIVERSITY OF SOUTH FLORIDA
Inventor： Shyam S. Mohapatra , Srinivas Nagaraj Bharadwaj , Subhra Mohapatra
IPC: C12N15/113 , C12N5/0784 , C12N5/0786
CPC classification number: C12N15/113 , A61K47/6807 , A61K47/6849 , A61K47/6929 , C12N5/0639 , C12N5/0645 , C12N5/0647 , C12N15/111 , C12N2310/141 , C12N2310/17 , C12N2320/30 , C12N2501/65 , C12Q1/6883 , C12Q2600/158 , C12Q2600/178
Abstract: Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved by increasing the miR-142 and/or miR-223 polynucleotides in a MDSC.
Abstract translation: 提供了用于调节骨髓来源的抑制细胞（MDSC）的分化的方法和组合物。 特别地，本文描述了可用于调节MDSC的分化的miR-142多核苷酸和miR-223多核苷酸。 可以通过增加MDSC中的miR-142和/或miR-223多核苷酸来实现MDSC群体或MDSC群体内的细胞的增加的分化。
-
公开(公告)号：US20240065983A1
公开(公告)日：2024-02-29
申请号：US18384528
申请日：2023-10-27
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra , Karthick Mayilsamy , Eleni Markoutsa , Andrew McGill
IPC: A61K9/51 , A61K31/4439 , A61K31/7105 , A61P31/14
CPC classification number: A61K9/5123 , A61K31/4439 , A61K31/7105 , A61P31/14
Abstract: A multi-functional broad-spectrum antiviral and anti-inflammatory nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a combination of therapeutic agents directed to the particular coronavirus encapsulated in a nanoparticle that is surface coated with a targeting moiety. For CoV-2 infections, an antiviral such as the PPAR-γ agonist leriglitazone (LG) and an siRNA targeting a conserved sequence of the virus can be encapsulated within a nanoparticle surface coated with a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
-
公开(公告)号：US11685885B1
公开(公告)日：2023-06-27
申请号：US16799413
申请日：2020-02-24
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra , Tao Wang
CPC classification number: C12M23/16 , B01L3/502715 , C12M23/12 , C12M25/14 , C12M41/26 , C12M41/36 , C12N5/0693 , G01N33/5011 , B01L2300/0627 , B01L2300/0819 , B01L2300/0829 , C12N2503/02 , C12N2513/00
Abstract: A 4D-perfused tumoroid-on-a-chip platform used in personalized cancer treatment. The platform includes a plate with a plurality of bottomless wells that resides atop a microfluidic channel layer, which in turn resides atop a surface acoustic wave (SAW) based sensor layer that is capable of measuring potential pH values of fluids disposed within the platform. The microfluidic channel layer includes a plurality of bioreactors, with each bioreactor including an inlet well, a culture well, and an outlet well. The inlet well, culture well, and outlet well form a closed system via fluid conduits spanning from the inlet well to the culture well, as well as from the culture well to the outlet well. Due to the fluid flow from the plate to the chip, and from the inlet well to the outlet well on the chip through the culture well, target cell (tumoroid) growth is promoted within the culture well.
-
公开(公告)号：US11198842B1
公开(公告)日：2021-12-14
申请号：US16799428
申请日：2020-02-24
Applicant: University of South Florida
Inventor： Subhra Mohapatra , Shyam S. Mohapatra , Tao Wang , Taylor Martinez
Abstract: An in vitro microfluidic device includes a device configured to model a blood-brain barrier. The device includes a center well in fluidic communication with each of an inlet and an outlet. Each of the center well, inlet, and outlet includes a porous membrane that separates a “blood” portion (a fluid flow portion) from a “brain” portion (a fluid containing portion). The porous membrane is seeded with endothelial cells such as the human venule endothelial cells (HUVECs) on the blood side, and with astrocytes on the brain side, to accurately model the blood-brain barrier. Fluid flows between the inlet, the center well, and the outlet to test the permeability of the porous membrane, thereby providing an accurate in vitro model of a blood-brain barrier.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.022 seconds)
